Tejara Capital Ltd Has $5.22 Million Stock Position in Roivant Sciences Ltd. $ROIV

Tejara Capital Ltd reduced its stake in Roivant Sciences Ltd. (NASDAQ:ROIV) by 47.7% during the second quarter, Holdings Channel.com reports. The fund owned 463,013 shares of the company’s stock after selling 422,649 shares during the quarter. Roivant Sciences makes up 2.4% of Tejara Capital Ltd’s investment portfolio, making the stock its 10th biggest position. Tejara Capital Ltd’s holdings in Roivant Sciences were worth $5,218,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Nuveen LLC purchased a new stake in shares of Roivant Sciences in the first quarter valued at approximately $31,988,000. Candriam S.C.A. raised its position in Roivant Sciences by 5,399.5% during the 2nd quarter. Candriam S.C.A. now owns 1,503,994 shares of the company’s stock valued at $16,951,000 after purchasing an additional 1,476,646 shares in the last quarter. Cutter Capital Management LP bought a new stake in Roivant Sciences during the 1st quarter valued at $13,117,000. Troluce Capital Advisors LLC purchased a new stake in shares of Roivant Sciences in the 1st quarter worth $7,187,000. Finally, Parkside Financial Bank & Trust grew its position in shares of Roivant Sciences by 113.3% during the 2nd quarter. Parkside Financial Bank & Trust now owns 1,309,541 shares of the company’s stock worth $14,759,000 after buying an additional 695,615 shares in the last quarter. Institutional investors own 64.76% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the stock. Bank of America raised their target price on shares of Roivant Sciences from $12.00 to $16.50 and gave the company a “neutral” rating in a research report on Thursday, September 18th. HC Wainwright lifted their price objective on shares of Roivant Sciences from $18.00 to $20.00 and gave the company a “buy” rating in a report on Thursday, September 18th. Guggenheim reaffirmed a “buy” rating and set a $25.00 target price on shares of Roivant Sciences in a research report on Friday, November 14th. Citigroup raised their price target on shares of Roivant Sciences from $25.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, November 11th. Finally, Weiss Ratings upgraded shares of Roivant Sciences from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Saturday, October 25th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $22.56.

Insiders Place Their Bets

In related news, major shareholder Vivek Ramaswamy sold 539,650 shares of the company’s stock in a transaction on Monday, November 17th. The stock was sold at an average price of $20.51, for a total value of $11,068,221.50. Following the transaction, the insider directly owned 33,653,756 shares of the company’s stock, valued at $690,238,535.56. This represents a 1.58% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Daniel Allen Gold sold 1,300,000 shares of the business’s stock in a transaction dated Wednesday, November 19th. The shares were sold at an average price of $20.23, for a total value of $26,299,000.00. Following the sale, the director owned 18,047,727 shares in the company, valued at approximately $365,105,517.21. The trade was a 6.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 8,483,561 shares of company stock valued at $143,557,750. Insiders own 10.80% of the company’s stock.

Roivant Sciences Stock Up 0.0%

ROIV opened at $20.87 on Friday. The company has a market cap of $14.51 billion, a P/E ratio of -37.27 and a beta of 1.23. The firm’s 50-day moving average price is $18.15 and its 200-day moving average price is $13.91. Roivant Sciences Ltd. has a 52-week low of $8.73 and a 52-week high of $21.35.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.